Despite an understanding of the pharmacological basis of cocaine abuse there is no effective pharmacotherapy, suggesting that pharmacotherapy may be impractical. An alternative approach is to: develop an immunotherapy that directly targets cocaine. We have generated a fully human anti-cocaine monoclonal antibody (mAb) with high affinity (Kd = 4 nM) for cocaine and selectivity over cocaine's inactive metabolites. This is a unique product. The immunogenicity of foreign proteins such as mouse mAbs is the major factor compromising the safety and efficacy of immunotherapeutic agents. The fully human sequence of our anti-cocaine mAb should be safe for repeated treatments in patients. In addition, the human sequence should confer long-term efficacy. Anti-cocaine mAbs do not cross the blood-brain-barrier but bind to cocaine in the peripheral circulation thereby sequestering cocaine in the periphery. Consequently, the anti-cocaine antibodies reduce all the central effects of cocaine. Accomplishing the aims of the proposed studies will advance this potential immunotherapeutic agent towards clinical trials by providing the initial indications of efficacy required for an IND application to the FDA. Prevention of relapse in cocaine abusers is the proposed primary indication of our human anti-cocaine mAbs.
The aim of this Phase I Fast-Track application is to add value to our immunotherapeutic agent by demonstrating the in vivo efficacy of the human anti-cocaine mAb. Efficacy will be defined as the ability to alter the pharmacokinetics of cocaine in vivo as measured by the ability to decrease the brain concentrations and increase the plasma concentrations of cocaine in mice. After successful completion of proposed Phase 1 milestones, Phase 2 studies will be implemented that will determine the stoichiometric relationship between cocaine and anti-cocaine mAb necessary to confer efficacy and will further determine efficacy of the anti-cocaine mAb in an animal model of cocaine abuse. A safe and effective passive immunotherapy for the treatment of cocaine abuse will be a valuable and unique product.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
4R44DA018538-02
Application #
6940913
Study Section
Special Emphasis Panel (ZRG1-BDCN-E (11))
Program Officer
Chiang, Nora
Project Start
2004-09-01
Project End
2005-11-30
Budget Start
2004-12-01
Budget End
2005-11-30
Support Year
2
Fiscal Year
2005
Total Cost
$436,401
Indirect Cost
Name
Phase 2 Discovery, Inc.
Department
Type
DUNS #
799563486
City
Cincinnati
State
OH
Country
United States
Zip Code
45219
Norman, Andrew B; Norman, Mantana K; Tabet, Michael R et al. (2011) Competitive dopamine receptor antagonists increase the equiactive cocaine concentration during self-administration. Synapse 65:404-11
Norman, Andrew B; Tabet, Michael R; Norman, Mantana K et al. (2011) The affinity of D2-like dopamine receptor antagonists determines the time to maximal effect on cocaine self-administration. J Pharmacol Exp Ther 338:724-8
Norman, Andrew B; Tabet, Michael R; Norman, Mantana K et al. (2011) Using the self-administration of apomorphine and cocaine to measure the pharmacodynamic potencies and pharmacokinetics of competitive dopamine receptor antagonists. J Neurosci Methods 194:252-8
Lape, Michael; Paula, Stefan; Ball Jr, William J (2010) A molecular model for cocaine binding by the immunotherapeutic human/mouse chimeric monoclonal antibody 2E2. Eur J Med Chem 45:2291-8
Norman, Andrew B; Norman, Mantana K; Buesing, William R et al. (2009) The effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-administration in rats. J Pharmacol Exp Ther 328:873-81
Thompson, Valerie B; Heiman, Justin; Chambers, James B et al. (2009) Long-term behavioral consequences of prenatal MDMA exposure. Physiol Behav 96:593-601
Norman, Andrew B; Tabet, Michael R; Norman, Mantana K et al. (2007) A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice. J Pharmacol Exp Ther 320:145-53
Norman, Andrew B; Tsibulsky, Vladimir L (2006) The compulsion zone: a pharmacological theory of acquired cocaine self-administration. Brain Res 1116:143-52